Are the New Biologics Effective in the Management of Postoperative Crohn's Disease?

Mourad, Fadi H; Maalouf, Rami G; Aoun, Roni; Gustavo Kotze, Paulo; Hashash, Jana G

Mourad, Fadi H; Maalouf, Rami G; Aoun, Roni; Gustavo Kotze, Paulo; Hashash, Jana G.

Afiliação

Mourad FH; Division of Gastroenterology and Hepatology, American University of Beirut, Beirut, Lebanon.
Maalouf RG; Division of Gastroenterology and Hepatology, American University of Beirut, Beirut, Lebanon.
Aoun R; Division of Gastroenterology and Hepatology, American University of Beirut, Beirut, Lebanon.
Gustavo Kotze P; Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, Brazil.
Hashash JG; Division of Gastroenterology and Hepatology, American University of Beirut, Beirut, Lebanon.

Inflamm Bowel Dis ; 30(3): 459-469, 2024 Mar 01.

Article em En | MEDLINE | ID: mdl-36879404

Review of the literature showed some encouraging results on the effectiveness of vedolizumab and ustekinumab in the prevention and treatment of postoperative Crohn's disease. However, more controlled studies comparing the new biologic agents with anti-tumor necrosis factor agents are needed.

Assuntos

Produtos Biológicos; Doença de Crohn; Humanos; Algoritmos; Produtos Biológicos/uso terapêutico; Doença de Crohn/tratamento farmacológico; Doença de Crohn/cirurgia; Ustekinumab/uso terapêutico; Inibidores do Fator de Necrose Tumoral/uso terapêutico

Palavras-chave

Crohn's disease recurrence; postoperative Crohn's disease; ustekinumab; vedolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doença de Crohn Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Inflamm Bowel Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Líbano

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google